Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive<sup>®</sup>

Wu, Junyu; Liu, Yan; Chen, Jiang-Ting; Xia, Ming; Zhang, Xiaomei

doi:10.4161/hv.21909

Cited by 16 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The WHO considers that HAV vaccines of different brand names are interchangeable 11 . The antigen content differs between vaccines, 14,15 however, all are considered safe and immunogenic 13,16-20 . Long-term persistence of antibodies has been shown with 2-dose vaccination schedules in adults 21,22 …”

Section: Introductionmentioning

confidence: 99%

Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review

Stuurman¹,

Marano

Bunge³

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The WHO recommends integration of universal mass vaccination (UMV) against hepatitis A virus (HAV) in national immunization schedules for children aged ≥1 year, if justified on the basis of acute HAV incidence, declining endemicity from high to intermediate and cost-effectiveness. This recommendation has been implemented in several countries. Our aim was to assess the impact of UMV using monovalent inactivated hepatitis A vaccines on incidence and persistence of anti-HAV (IgG) antibodies in pediatric populations. We conducted a systematic review of literature published between 2000 and 2015 in PubMed, Cochrane Library, LILACS, IBECS identifying a total of 27 studies (Argentina, Belgium, China, Greece, Israel, Panama, the United States and Uruguay). All except one study showed a marked decline in the incidence of hepatitis A post introduction of UMV. The incidence in non-vaccinated age groups decreased as well, suggesting herd immunity but also rising susceptibility. Long-term anti-HAV antibody persistence was documented up to 17 y after a 2-dose primary vaccination. In conclusion, introduction of UMV in countries with intermediate endemicity for HAV infection led to a considerable decrease in the incidence of hepatitis A in vaccinated and in non-vaccinated age groups alike.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review

Stuurman¹,

Marano

Bunge³

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…8 Healive Ò also provided lasting protection in healthy individuals with 2-dose schedule and was effective in curbing outbreaks of hepatitis A with one single dose. 9 China is one of the world's few countries, in which both inactivated HA vaccine and live attenuated hepatitis A vaccine Figure 2. Five-year change of immune response in inactivated or attenuated hepatitis A vaccine group.…”

Section: Discussionmentioning

confidence: 99%

“…11,12 In addition, the live vaccines do not provide post-exposure protection because of slow immune response to the vaccines and cannot be used for emergency immunization during control of outbreaks. 9,10 Hence, for safety concern, the remaining 4 rich municipalities/provinces (Beijing, Tianjin, Shanghai, Jiangsu) purchased the more expensive, inactivated HAV vaccines for the routine childhood immunization program. Barriers to the introduction of universal inactivated HA vaccine immunization of children include higher vaccine prices and 2-dose schedule with availability of simpler one-dose attenuated HA vaccine schedule.…”

Section: Discussionmentioning

confidence: 99%

Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine

Zhang

Zhu

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In China, both inactivated hepatitis A (HA) vaccine and live attenuated HA vaccine are available. We conducted a trial to evaluate 5-year immune persistence induced by one dose of inactivated or live attenuated HA vaccines in children. Subjects with no HA vaccination history had randomly received one dose of inactivated or live attenuated HA vaccine at 18-60 months of age. Anti-HAV antibody concentrations were measured before vaccination and at the first, second, and fifth year after vaccination. Suspected cases of hepatitis A were monitored during the study period. A total of 332 subjects were enrolled and 182 provided evaluable serum samples at all planned time points. seropositive rate at 5 y was 85.9% in the inactivated HA vaccine group and 90.7% in the live attenuated HA vaccine group. GMCs were 76.3% mIU/ml (95% CI: 61.7 - 94.4) and 66.8mIU/ml (95% CI: 57.8 - 77.3), respectively. No significant difference in antibody persistence between 2 groups was found. No clinical hepatitis A case was reported. A single dose of an inactivated or live attenuated HA vaccine at 18-60 months of age resulted in high HAV seropositive rate and anti-HAV antibody concentrations that lasted for at least 5 y.

show abstract

“…An anti-HAV IgG value ≥ 20 mIU/ml was considered protective, and also as seropositive (seroconversion) after vaccination. [17][18][19] Therefore, the term "seroconversion" is meaning of "seroprotection. "…”

Section: Conflict Of Interestmentioning

confidence: 99%

Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines

Liu

Wushouer²,

Gou

et al. 2013

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive^®

Cited by 16 publications

References 20 publications

Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review

Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review

Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine

Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines

Contact Info

Product

Resources

About

Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive®

Cited by 16 publications

References 20 publications

Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review

Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review

Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine

Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines

Contact Info

Product

Resources

About

Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive^®